血小板与结核病相关研究进展  

Progress in platelets and tuberculosis

作　　者：吴逢英 李远春 姜旭 刘晓清[1] Wu Fengying;Li Yuanchun;Jiang Xu;Liu Xiaoqing(Division of Infectious Diseases,Department of Internal medicine,State Key Laboratory of Complex Severe and Rare Disease,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;Medical Research Center,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院疑难重症及罕见病国家重点实验室感染内科,北京100730 [2]中国医学科学院北京协和医学院北京协和医院疑难重症及罕见病国家重点实验室医学研究中心,北京100730

出　　处：《中华结核和呼吸杂志》2024年第2期183-189,共7页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：中央高水平医院临床科研专项基金(2022-PUMCH-C-013)。

摘　　要：血小板是介导机体止血凝血的经典细胞,近年来,血小板相关免疫机制和临床研究成为了国内外结核病的研究热点之一。血小板通过参与系统性炎症反应和肺部免疫反应,在结核病中发挥负向调节作用。这主要通过血小板与结核分枝杆菌的直接接触和与免疫细胞的相互作用实现,此外,结核病患者常出现血小板增多症,越来越多的临床研究证明以抗血小板治疗为主的宿主导向疗法在控制结核病方面显示出明显临床获益。血小板抑制可能成为结核病治疗的新策略。本文旨在阐述血小板与结核病相关的病理生理机制和临床研究的进展。Platelets are important cells in hemostatic and coagulative reactions.Interestingly,platelets-related immunopathological mechanism and clinical research have become one of the hot research topics in tuberculosis at home and abroad in recent years.Platelets get involved in host chronic inflammation and pulmonary immune response,thus playing a negative regulatory role in tuberculosis.This is achieved through direct internalization of Mycobacterium tuberculosis and indirect interaction with immune cells.In addition,patients with tuberculosis often have thrombocytosis,and there is increasing evidence that anti-platelet therapy as a host-directed therapy has demonstrable clinical benefit in tuberculosis control.Platelet inhibition may be an emerging therapeutic strategy for tuberculosis.This review aims to highlight the research progress in platelets and tuberculosis.

关 键 词：病理生理机制 结核病治疗 血小板增多症 抗血小板治疗 结核分枝杆菌 结核病患者 负向调节 免疫细胞 

分 类 号：R52[医药卫生—内科学]